Send us Fan Mail For decades, AL amyloidosis was a disease for which there were no FDA-approved therapies, treatments we did have were often borrowed from multiple myeloma, and resulted in poor outcomes for patients. It is one of the 7,000 diseases classified as a “rare disease,” and over 95% of those have no FDA-approved drug. In 2018 that all changed and it created a cascade of drug approvals, accompanied by a flourishing pipeline of diverse clinical trials. This has launched a world of accelerated research on amyloidosis, giving hope to patients. In today’s episode we’ll be talking with Dan about “hope” and how life with amyloidosis is brighter than ever before. For an overview of amyloidosis, please see episode 2 (for clinicians) or episode 3 (for patients).
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_01Hi everyone. Welcome to the All Things Amyloid Podcast, where we feature patients, caregivers, and clinicians who discuss amyloidosis, a rare and incurable disease. Amyloidosis occurs when the body builds up abnormal amounts of misfolded amyloid protein, which can lead to serious and life-threatening outcomes. I'm your host, McKenzie, an amyloidosis patient and founder of Mackenzie's Mission. Our goal for this podcast is to raise awareness and share firsthand what it's like to live with this disease, to care for those affected by it, and to treat it.
SPEAKER_01We hope this leads to earlier diagnosis and start of treatment, which will improve patient lives. For decades, AL amyloidosis was a disease for which there were no FDA-proof therapies. Treatments we did have were often borrowed from multiple myeloma and resulted in poor outcomes for patients. It is one of the 7,000 diseases classified as a rare disease, and over 95% of those diseases have no FDA-proof drugs. In 2018, that all changed.
SPEAKER_01And it created a cascade of drug approvals accompanied by a flourishing pipeline of diverse clinical trials. This has launched a world of accelerated research on amyloidosis, giving hope to countless patients. In today's episode, we'll be talking with Dan about hope and how life with amyloidosis is brighter than ever before. Welcome, Dan. It's wonderful to have you back on the podcast.
SPEAKER_00Hey, Mackenzie. I'm delighted to be back. Thanks a lot for inviting me.
SPEAKER_01Of course. And I'd love to start just by talking about how life with amyloidosis is brighter than ever.
SPEAKER_00Yeah, you know, I totally agree that amyloidosis is no longer a death sentence or sort of a near-death sentence. There's definitely a lot of hope, and that's a wonderful world. Wonderful, wonderful word when you're dealing with a disease like that. That really does sound frightening, certainly, when I first diagnosed as likely having amyloidosis. Of course, my wife and I, like everyone else, would um immediately went to Google and Googled amyloidosis.
SPEAKER_00And um especially at that point, um, this is several years uh back. You know, it's that pretty, you know, and you look up from the computer saying, you know, I may just have a year or two to live or something like that. That's frightening.
SPEAKER_01Yeah, this is just about the exact same experience that I had uh back in 2017. And I I too went to Dr. Google and was told, you know, you have months to 18 months to live, and it's devastating. But unfortunately, that's the nature of the internet in Google. There's outdated and incorrect information that remains accessible on the internet for a very long time. And this can really confuse patients who aren't yet able to distinguish right the old state of amyloidosis versus like the new state where we are now of today's amyloidosis.
SPEAKER_01But I'm sure the news that you read was really upsetting.
SPEAKER_00Well, yeah, of course it is. Um, you know, because you go from a situation where um you may have been experiencing some issues, but then all of a sudden you're reading online that, you know, you may have a year to live or something like that. So um, of course you're frightened. Um some things immediately gave me a ray of hope. Um, my doctor, I first first of all, I was very fortunate to live um within minutes of a sex uh of a center of excellence for amylosis.
SPEAKER_00Um, so that was very, very helpful. Um, my doctors wanted to start treatment immediately, so it gave me a sense that I was actually doing something. Um, but also um for me, another real ray of hope. I think I got the standard cyborg-D chemo um combination um that was at that point kind of standard for treatment for cardiac amyloidosis, AL amyloidosis.
SPEAKER_00But also I was um again, because I was in the hands of a really good doctor who was in the national community um really searching, um doing a lot of this groundbreaking work searching for um treatments for amyloidosis. Um she was starting a study at OHSU, so I was enabled to enroll in a clinical trial. In fact, I was patient patient number one at OHSU um where Deritumamab was added to the standard cyborg D cocktail um for amyloidosis.
SPEAKER_00Um so I had really good care early on, uh started aggressive treatment and participated in a study um right off the bat. So that made me feel much more like I was sort of actively taking on this medical fight, uh, and it gave me a lot of hope uh to start this journey back to health.
SPEAKER_01Yeah, I I very much appreciate your comment about being under expect expert care and really seeking that out. Right. I, you know, I echo the those that experience, you know, within hours of my diagnosis. My aunt, who uh works in oncology, got it got got on the ball. And I had an appointment two weeks later at the Mayo Clinic, you know, another center of excellence for amyloidosis. And there's great comfort in that and knowing that the people who are caring for you are really at the front lines of this disease and and up to date with all of the opportunities.
SPEAKER_01Like you mentioned, the the clinical trial with adding deratumumab to the cyborg D, you know, those kind of things that really advance our knowledge of amyloidosis is so important. And I also agree with you that at this stage, that being kind of the newly diagnosed, you're just starting to learn about the prognosis and the treatment options that are available to patients, is probably the most terrifying time. And it's really the fear of the unknown, the fear of being alone that I think really stands out as a patient.
SPEAKER_00Yeah, that's interesting. Had you even really heard of amyloidosis before you were diagnosed?
SPEAKER_01Never, never heard of it.
SPEAKER_00And so, you know, that of course contributes to that fear of the unknown and being alone. Um, you know, in a sense, you kind of don't know where to turn, who to lean on, and that can be really terrifying. You know, you just feel alone in this um very frightening experience. For me, to feeling like I was in good medical hands and starting aggressive treatment very soon, um, even before that, actually, um, I found the amyloidosis support group, found a reference to that online as well.
SPEAKER_00So Dr. Google can actually do some good things as well. Um, the amylosis support groups run by fabulous people. Um, and I was also really fortunate that there was a meeting about to take place in Portland, and I went to meet uh that meeting, and that was a huge ray of hope for me. Um it allowed me to connect with other amyloidosis patients, hear their stories, um, hear what others had gone through.
SPEAKER_00Um, I saw a number of people who were successfully undergoing treatment and had done well, and that of course was a huge ray of hope. A lot of people gave me a sense of what might lie ahead in this journey. Um, so seeing that knowledge looking forward was really powerful as well. The amylogosis support group also has a lot of medical information and can provide lots of sources for information, including reliable, you know, much more reliable and up-to-date sources on the web.
SPEAKER_00And so just that wealth of information um was was really helpful as well. But perhaps most importantly, um, just knowing that I wasn't alone, suddenly I was with this group of people who had gone through similar experiences who could give me their wisdom, give me encouragement. And I just knew that I wasn't alone in this fight. And that really helped give me strength and knowledge and empowerment that I needed to go forward. And it also really underlined for me the importance of educating myself so I could be that engaged um self-advocate.
SPEAKER_00I don't know, Mackenzie, did you um, you know, make efforts to educate yourself as well?
SPEAKER_01Absolutely. And you know, you make a really important point about amyloidis support groups and and having that community and knowing that there are other people out there facing the same situation you are that are willing to share and support one another and encourage others. It really gives you as a patient energy to be an active participant, like you mentioned, in in your disease. And I too found great comfort in the amyloidosis community and really used that as an opportunity to figure out how to educate myself about amyloidosis.
SPEAKER_01Because, you know, like we we talked about earlier, Dr. Google can be hit or miss. Um, and there are some great resources out there, but you know, it's important to think about where and how you educate yourself, what resources are you using? And so I very quickly found um, in addition to Miro's group, the Amyloidosis Research Consortium and the Amyloidosis Foundation, and a lot of the information I learned about the disease also came from healthcare institutions who are centers of excellence.
SPEAKER_01Um, there's a lot of great information that all of those sites have, and I really used those to strengthen my understanding about amyloidosis, and like you said, use that to educate yourself and become kind of an engaged and a more powerful self-advocate. But you also talk about being in the clinical trial, and I want to circle back to this. I am a really passionate believer in the importance of research and clinical trials, right? That's the only way that we learn and develop new therapies to treat this disease.
SPEAKER_01And today we're very fortunate. We do have a handful of FDA-proof drugs, which is a tremendous accomplishment and such accomplishment in such a short amount of time. But what I'm really truly hopeful for is the pipeline of clinical trials that are going on now. Right? They're they range from focusing on AL to ATTR amyloidosis. They're doing research on cutting-edge non-invasive diagnostic imaging or developing drugs to remove the amyloid fibrils that have deposited in your organs, right?
SPEAKER_01What are called depleter drugs and everything in between. It's it's just truly incredible the landscape of amyloidosis and and how it's evolved over what the last five to ten years. It's it's astounding. And research and publications also seem to be gaining a lot of ground and adding to our body of knowledge and and really accelerating the dissemination of what's being discovered about amyloidosis.
SPEAKER_00I mean, there are really some amazing researchers focusing on amyloidosis today. I've had, you know, the the um opportunity to be involved with some of them, you know, and seeing the the professionals running these studies, the doctors and medical experts running these studies, um, was really impressive to me and that that did give me a lot of hope. And you can sort of see that in the sort of amazing pace of important breakthroughs um that's going on today.
SPEAKER_00You know, that's that's obviously fabulous news, but I think it also underlines the importance of patients doing their own research as well, or at least who are following, you know, these many medical developments in amyladosis. Um, you know, and that can help you be able to ask your doctor the most relevant questions about your treatment, learn about studies or new drugs that can be beneficial in your case as well.
SPEAKER_00So, you know, finding ways to follow, to try to follow and um stay on top of some of this knowledge is really important. You know, getting on relevant listserves, email lists, attending meetings of the amyloidosis support group, and you know, sort of doing your own informed poking around on the web, all while being armed with the knowledge, um, with more knowledge, uh, to better analyze the information that you find.
SPEAKER_01Absolutely. That's a that's a great point that you make. And another area that I think also gives us great hope, like you touched touched on, is the dramatic education that's going on in the healthcare community. Uh, for example, we we heard from Dr. Ron Matellis, who's a cardiologist and the co-director of the amyloid program at Stanford. And he said that in cardiology, particularly the topic of cardiac amyloidosis, whether in the form of AL or TTR, is really the hottest topic across the country right now.
SPEAKER_01And he was mentioning at conferences it's now a mainstream agenda item. It's standing room only. So we know firsthand that within our amyloidosis speakers bureau, right, one of our targets is the residency programs. And that seems to be the fastest growing area that we have. Uh, more and more of our residency programs are inviting us to present. And in the audience, we find that there are also fellows and attending physicians who are also participating.
SPEAKER_01And the crowd just far surpasses the residency program. So, whether from educating future physicians in medical schools or current practicing clinicians in residency programs, the race seems to be on for amyloidosis in a very big way.
SPEAKER_00So it's certainly um a privilege for me to be part of that organization, of your organization. But I think, you know, looking across the country, there's a growing um number of centers of excellence. It's not just Mayo in Boston anymore. You know, I was sort of relatively out in the boondocks in Portland, Oregon. Um, but Oregon Health Science Um University is a center of excellence. And as I said, was one of the key institutions behind a very important study in bringing amyloidosis, uh, excuse me, in bringing Derotuma Mab online as an important um first-level treatment for amyloidosis.
SPEAKER_00A lot easier for patients to have access to good health care in a lot more places on the West Coast, OHSU, Stanford, for example, and more. Um, that can really improve timelines for diagnosis. Um, that's really critical since early detection is so important before damaged um tamyidosis goes too far, and um, you know, can reduce patients' need to travel, and that can be a real barrier for a lot of people.
SPEAKER_00This really means huge progress for patients, which is fantastic.
SPEAKER_01Absolutely. I'm glad you mentioned this because you you you make a great point in that it's it's not just about the clinical trials and the drugs, but also the access to those kind of things. And so seeing the progression of our centers of excellence, like like you said, it used to be Mayo and BU. And over the years, we've gotten so many credible centers of excellence come online, right? OHSU, Stanford, Columbia, you know, you name it, but there's so much greater access for patients to be able to seek care at one of these institutions.
SPEAKER_01So like you said, that is huge progress for patients. And honestly, I suspect we could keep talking for hours, but perhaps you could offer some closing thoughts that you'd like our patients who are listening to take away.
SPEAKER_00You know, I began my amyloidosis journey as we've talked about with a lot of fear and foreboding about the future. Um, I'm very fortunate, um, in part, um, not in part, really, in progress we've made in diagnosing and treating amylosis. Very fortunate to be in a place in life where the disease really doesn't curtail um what I do. Um, I work full-time.
SPEAKER_00Um, I travel, and in fact, now I've sort of combined my traveling and working by being able to work remotely even abroad. Um, I ride my bike a lot. Um, I do outrigger canoe races with my wife and our two-person outrigger canoe. I do long hikes with my family, and so I feel very fortunate to be able to continue to do those things then that I love in life. And especially this past summer, um, which was almost seven years after my diagnosis on the aisle at her wedding, which sort of makes me emotional just to say it.
SPEAKER_00But you know, it was a wonderful event. Um, and I feel very fortunate that um because of all this hope and progress uh in treating amyloidosis, I was able to be there and be part of that event. So amylidosis doesn't really affect me physically a lot these days. Um, but of course, I still think a lot about what I've been through and recognize this gift of time, essentially, that modern medicine has given me and all the progress and the research and the treatment in amyloidosis has given me.
SPEAKER_00And so, you know, it it kind of helps me remember the importance of living for today. Um I I try not to put off things that that I want to do someday. I I I try to do them. Um, but also, of course, I feel a lot of gratitude for the professionals and caregivers that enabled me to get to this point. Um, and I also feel thankful for people like you who are, you know, took your experience and are uh, you know, you're turning it into something good to educate um both professionals as well as patients about this disease and and really the hope um that we can now experience with it.
SPEAKER_01Yeah, I'm I'm so glad to hear that you're kind of back living life and doing all of the things that bring you joy and like you said, not not putting anything off that you can experience now. So I'm so glad that you're at a point where you're able to live your life to the fullest and make the most of it every day. So um I'm so glad that you shared that with our audience. I think it's nice to have hope for them, right? But most importantly, thank you so much, Dan, for joining us today.
SPEAKER_01It's been an absolute pleasure to have you on our podcast. And I'm I'm very grateful for you taking the time to speak with us today and also all the work you do at the Amy Lados Speakers Bureau. So thanks so much.
SPEAKER_00Pleasure to talk to you.
SPEAKER_01Of course. And I for our listeners, I just want to add a few parting comments of my own. Um, you know, Dan makes some really great points. And in addition to those, I want to offer a number of things. First, you know, we talk about this over and over again, but the time to diagnose remains such a critical part of a patient's journey. And a good number of patients, even today, are still being diagnosed too late. So for patients out there, please don't wait.
SPEAKER_01Advocate for yourself. And it's important to remember that after all, it's your life. And waiting affects you. So don't wait. Two, there is still value, and it it does matter that you're under the care of an amyloidosis expert or someone who's at least familiar with the disease, right? You want to make sure that they're a part of your care team, whether that be directly or supporting a more local team that you have.
SPEAKER_01Three, if you're given an opportunity to participate in the clinical trial, please at least consider it. Try to learn more about the trial, what they're doing. Because that's how we get early access to new treatments, often at no cost to the patient. But it really helps advance the treatment options for patients that will come after us. And that is so important. Next, the the speed at which advancements are happening in the world of amyloidosis is astounding.
SPEAKER_01And there really is so much hope out there. And so I I wanna I wanna highlight that. Amyloidosis it seems to be that it's on a path to becoming a manageable chronic disease for all types of amyloidosis. So that might not be too far in the near distant future, and you know, maybe even one day we'll get a cure for this disease. And then lastly, most importantly, keep fighting, right?
SPEAKER_01There's there's so much to be hopeful for. And don't ever give up. Thank you for listening to the All Things Amyloid Podcast. If you find our podcast informative, please follow and share it with others. If you want to learn more about the work we're doing at McKenzie's Mission, please visit mm713.org. We'd also like to thank AstraZeneca Pharmaceuticals, Alexion Pharmaceuticals, Al Nylon Pharmaceuticals, and Bridge Biopharma for their sponsorship to help raise awareness about amyloidosis.
SPEAKER_01We hope you stay tuned for future episode drops. Thanks for listening.
Send us Fan Mail Adapted from his video, in this episode of All Things Amyloid, Dr. Mat Maurer, cardiologist at Columbia University Irving Medical Center discusses the importance of developing a broad differential in...
Send us Fan Mail It’s that time of year for Medicare Open Enrollment - a season that impacts so many of our amyloidosis patients. I’ll be speaking with Ann Kayrish, an expert in this area and someone who worked for...
Send us Fan Mail Caregiving seems to be a universal role that many of us play at some time in our lives, whether we are ready for it or not. It may be for a child, parent, spouse, family member, or friend who is facing...
Send us Fan Mail It’s that time of year for Medicare Open Enrollment - a season that impacts so many of our amyloidosis patients. I’ll be speaking with Ann Kayrish, an expert in this area and someone who worked for...
Send us Fan Mail Amyloidosis patients often experience GI issues, both before and after diagnosis. The commonness of these symptoms can increase the difficulty of diagnosing amyloidosis. Adapted from her video...